Cachexia and sarcopenia: Emerging syndromes of importance in dogs and cats

Journal of Veterinary Internal Medicine

Volumn 26, Issue 1, 2012, Pages 3-17

  Freeman, L M ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Inflammation; Lean body mass; Muscle condition score; Nutrition

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; CACHEXIA; CAT; CAT DISEASE; DOG; DOG DISEASE; MUSCLE ATROPHY; PATHOPHYSIOLOGY;

ANIMALS; CACHEXIA; CAT DISEASES; CATS; DOG DISEASES; DOGS; SARCOPENIA;

CANIS FAMILIARIS;

EID: 84855745955     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00838.x     Document Type: Article

References (135)

1. Katz AM, Katz PB. Diseases of the heart in the works of Hippocrates. Br Heart J 1962;24:257-264.
2. Doehner W, Anker SD. Cardiac cachexia in early literature: A review of research prior to Medline. Int J Cardiol 2002;85:7-14.
3. von Haehling S, Lainscak M, Springer J, et al. Cardiac cachexia: A systematic overview. Pharmacol Therapeut 2009;121:227-252.
4. Morley JE, Thomas DR, Wilson MMG. Cachexia: Pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-743.
5. Lowry SF, Perez JM. The hypercatabolic state. In: Shils ME, Shike M, Ross AC, et al, eds. Modern Nutrition in Health and Disease, 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1381-1400.
6. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053.
7. Anker SD, Negassa A, Coats AJS, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet 2003;361:1077-1083.
8. Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia. Nutr Rev 1994;52:340-347.
9. Baez JL, Michel KE, Sorenmo K, et al. A prospective investigation of the prevalence and prognostic significance of weight loss and changes in body condition in feline cancer patients. J Fel Med Surg 2007;9:411-417.
10. Scarlett JM, Donoghue S. Associations between body condition and disease in cats. J Am Vet Med Assoc 1998;212:1725-1731.
11. Doria-Rose VP, Scarlett JM. Mortality rates and causes of death among emaciated cats. J Am Vet Med Assoc 2000;216:347-351.
12. Mallery KF, Freeman LM, Harpster NK, et al. Factors contributing to the decision for euthanasia of dogs with congestive heart failure. J Am Vet Med Assoc 1999;214:1201-1204.
13. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990;81:518-527.
14. Carvalho RF, Castan EP, Coelho CA, et al. Heart failure increases atrogin-1 and MuRF1 gene expression in skeletal muscle with fiber type-specific atrophy. J Mol Histol 2010;41:81-87.
15. Oreopoulos A, Kalantar-Zadeh K, McAlister FA, et al. Comparison of direct body composition assessment methods in patients with chronic heart failure. J Card Fail 2010;16:867-872.
16. Freeman LM, Kehayias JJ, Roubenoff R. Letter to the editor. J Vet Intern Med 1996;10:99-100.
17. Evans WJ, Morley JE, Argiles J, et al. Cachexia: A new definition. Clin Nutr 2008;27:6.
18. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 2010;29:154-159.
19. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-495.
20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sarcopenia in older people. Age Ageing 2010;39:412-423.
21. Swimmer RA, Rozanski EA. Evaluation of the 6-minute walk test in pet dogs. J Vet Intern Med 2011;25:405-406.
22. Freeman LM, Rush JE, Kehayias JJ, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998;12:440-448.
23. Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: A meta-analysis. Am Heart J 2008;156:13-22.
24. Webster J, Hesp R, Garrow J. The composition of excess weight in obese women estimated by body density, total body water and total body potassium. Hum Nutr Clin Nutr 1984;38:299-306.
25. Wells JCK, Rewtrell MS, Williams JE, et al. Body composition in normal weight, overweight and obese children: Matched case-control analyses of total and regional tissue masses, and body composition trends in relation to relative weight. Int J Obesity 2006;30:1506-1513.
26. Slupe JL, Freeman LM, Rush JE. Association of body weight and body condition with survival in dogs with heart failure. J Vet Intern Med 2008;22:561-565.
27. Finn E, Freeman LM, Rush JE, et al. The relationship between body weight, body condition, and survival in cats with heart failure. J Vet Intern Med 2010;24:1369-1374.
28. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381-410.
29. Michel KE, Sorenmo K, Shofer FS. Evaluation of body condition and weight loss in dogs presented to a veterinary oncology service. J Vet Intern Med 2004;18:692-695.
30. Weeth LP, Fascetti AJ, Kass PH, et al. Prevalence of obese dogs in a population of dogs with cancer. Am J Vet Res 2007;68:389-398.
31. Laflamme DP. Development and validation of a body condition score system for dogs. Canine Pract 1997;22:10-15.
32. Laflamme DP. Development and validation of a body condition score system for cats. Feline Pract 1997;25:13-18.
33. Glanton CW, Hypolite IO, Hshieh PB, et al. Factors associated with improved short term survival in obese end stage renal disease patients. Ann Epidemiol 2003;13:136-143.
34. Fleischmann E, Teal N, Dudley J, et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999;55:1560-1567.
35. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis 2007;49:581-591.
36. Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clinic Proc 2010;85:991-1001.
37. Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: Analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004;65:597-605.
38. Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002;13:1061-1066.
39. Leavey SF, Strawderman RL, Jones CA, et al. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998;31:997-1006.
40. Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001;16:2386-2394.
41. Wolfe RA, Ashby VB, Daugirdas JT, et al. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000;35:80-88.
42. Kopple JD, Zhu X, Lew NL, et al. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999;56:1136-1148.
43. Johansen KL, Young B, Kaysen GA, et al. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004;80:324-332.
44. Lowrie EG, Li Z, Ofsthun N, et al. Body size, dialysis dose and death risk relationships among hemodialysis patients. Kidney Int 2002;62:1891-1897.
45. Kaizu Y, Tsunega Y, Yoneyama T, et al. Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients. Clin Nephrol 1998;50:44-50.
46. Parker VJ, Freeman LM. Association between body condition and survival in dogs with acquired chronic kidney disease. J Vet Intern Med. Online September 28, 2011; doi: 10.1111/j.1939-1676.2011.00805.x.
47. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: Role of comorbidity and systemic inflammation. Arch Intern Med 2005;165:1624-1629.
48. Roubenoff R. Rheumatoid cachexia: A complication of rheumatoid arthritis moves into the 21st century. Arthritis Res Therapy 2009;11:108.
49. Marti S, Munoz X, Rios J, et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Resp J 2006;27:689-696.
50. Wanke C, Kotler D, Committee HIVWCC. Collaborative recommendations: The approach to diagnosis and treatment of HIV wasting. JAIDS 2004;37(Suppl 5):S284-S288.
51. Biggs ML, Mukamal KJ, Luchsinger JA, et al. Association between adiposity in midlife and older age and risk of diabetes in older adults. J Am Med Assoc 2010;303:2504-2512.
52. Lang T, Streeper T, Cawthon P, et al. Sarcopenia: Etiology, clinical consequences, intervention, and assessment. Osteoporosis Int 2009;21:543-559.
53. Meyer J, Stadtfeld G. Investigation on the body and organ structure of dogs. In: Anderson RS, ed. Nutrition of the Dog and Cat. Oxford, UK: Pergamon Press; 1980:15-30.
54. Lawler DF, Larson BT, Ballam JM, et al. Diet restriction and ageing in the dog: Major observations over two decades. Br J Nutr 2009;99:793-805.
55. Toth MJ, Gottlieb SS, Fisher ML, et al. Daily energy requirements in heart failure patients. Metabolism 1997;46:1294-1298.
56. Riley M, Elborn JS, McKane WR, et al. Resting energy expenditure in chronic cardiac failure. Clin Sci 1991;80:633-639.
57. Ogilvie GK, Walters LM, Salman MD, et al. Resting energy expenditure in dogs with nonhematopoietic malignancies before and after excision of tumors. Am J Vet Res 1996;57:1463-1467.
58. Arutyunov GP, Kostyukevich OI, Serov RA, et al. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol 2008;125:240-245.
59. Krack A, Sharma R, Figulla HR, et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005;26:2368-2374.
60. Freeman LM, Rush JE, Cahalane AK, et al. Evaluation of dietary patterns in dogs with cardiac disease. J Am Vet Med Assoc 2003;223:1301-1305.
61. Torin DS, Freeman LM, Rush JE. Dietary patterns of cats with cardiac disease. J Am Vet Med Assoc 2007;230:862-867.
62. Woods SC, D'Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab 2008;93:S37-S50.
63. Laviano A, Inui A, Marks DL, et al. Neural control of the anorexia-cachexia syndrome. Am J Physiol Endocrinol Metab 2008;295:E1000-E1008.
64. Schwenke DO, Tokudome T, Kishimoto I, et al. Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology 2008;149:5172-5176.
65. Deboer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile. Endocrinology 2008;149:827-835.
66. DeBoer MD. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 2008;24:806-814.
67. Lund LH, Williams JJ, Freda P, et al. Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. Eur J Heart Fail 2009;11:789-794.
68. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001;104:1430-1435.
69. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004;110:3674-3679.
70. Akashi YJ, Palus S, Datta R, et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol 2009;137:267-275.
71. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005;128:1187-1193.
72. Strassburg S, Anker SD, Castaneda TR, et al. Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats. Am J Physiol Endocrinol Metab 2008;295:E78-E84.
73. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
74. Hamid T, Gu Y, Ortines RV, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: Role of nuclear factor-kappaB and inflammatory activation. Circulation 2009;119:1386-1397.
75. Moresi V, Pristera A, Scicchitano BM, et al. Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. Stem Cells 2008;26:997-1008.
76. Anker SD, Coats AJS. How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach. Int J Cardiol 2002;86:123-130.
77. Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463-1472.
78. Wiese D, Lashner B, Seidner D. Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutr Clin Pract 2008;23:551-556.
79. Meurs KM, Fox PR, Miller MW, et al. Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure. Am J Vet Res 2002;63:640-642.
80. Sheth T, Parker T, Block A, et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002;90:496-500.
81. Matsumori A, Ono K, Nishio R, et al. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: A possible mechanism for its effect in heart failure. Circulation 1997;96:1386-1389.
82. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-1312.
83. Molenaar P, Chen L, Parsonage WA. Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting. Br J Pharmacol 2006;147:583-586.
84. Yu Z, Li P, Zhang M, et al. Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli. PLoS ONE 2008;3:e2086.
85. Lenk K, Schur R, Linke A, et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 2009;11:342-348.
86. McFarlane C, Plummer E, Thomas M, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006;209:501-514.
87. Gruson D, Ahn SA, Ketelslegers JM, et al. Increased plasma myostatin in heart failure. Eur J Heart Fail 2011;13:734-736.
88. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997;94:12457-12461.
89. Kambadur R, Sharma M, Smith TP, et al. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997;7:910-916.
90. Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997;17:71-74.
91. Clop A, Marcq F, Takeda H, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 2006;38:813-818.
92. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-2688.
93. Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genetics 2007;3:e79.
94. George I, Bish LT, Kamalakkannan G, et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail 2010;12:444-453.
95. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-1488.
96. Heineke J, Auger-Messier M, Xu J, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010;121:419-425.
97. Benny Klimek ME, Aydogdu T, Link MJ, et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Comm 2010;391:1548-1554.
98. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-543.
99. Whittemore LA, Song K, Li X, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Comm 2003;300:965-971.
100. Siriett V, Salerno MS, Berry C, et al. Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther: J Am Soc Gene Ther 2007;15:1463-1470.
101. Dalla Libera L, Ravara B, Gobbo V, et al. Skeletal muscle proteins oxidation in chronic right heart failure in rats: Can different beta-blockers prevent it to the same degree? Int J Cardiol 2010;143:192-199.
102. Hryniewicz K, Androne AS, Hudaihed A, et al. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail 2007;9:464-468.
103. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: A pilot study. Int J Cardiol 2006;106:319-322.
104. Vaz Perez A, Doehner W, von Haehling S, et al. The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2010;141:39-43.
105. McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007;28:829-835.
106. Lafontan M, Moro C, Sengenes C, et al. An unsuspected metabolic role for atrial natriuretic peptides: The control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Arterioscler Thromb Vasc Biol 2005;25:2032-2042.
107. Rolland Y, Czerwinski S, Abellan Van Kan G, et al. Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12:433-450.
108. Doehner W, Pflaum CD, Rauchhaus M, et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 2001;145:727-735.
109. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762.
110. Fonfara S, Hetzel U, Tew SR, et al. Leptin expression in dogs with cardiac disease and congestive heart failure. J Vet Intern Med 2011;25:1017-1024.
111. Laoutaris ID, Vasiliadis IK, Dritsas A, et al. High plasma adiponectin is related to low functional capacity in patients with chronic heart failure. Int J Cardiol 2009;144:230-231.
112. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-973.
113. Smiechowska J, Utech A, Taffet G, et al. Adipokines in patients with cancer anorexia and cachexia. J Invest Med 2010;58:554-559.
114. Kerem M, Ferahkose Z, Yilmaz UT, et al. Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol 2008;14:3633-3641.
115. Penna F, Bonetto A, Muscaritoli M, et al. Muscle atrophy in experimental cancer cachexia: Is the IGF-1 signaling pathway involved? Int J Cancer 2010;127:1706-1717.
116. Petretta M, Colao A, Sardu C, et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007;17:288-296.
117. Gotherstrom G, Bengtsson BA, Bosaeus I, et al. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007;92:1442-1445.
118. Rosenthal N, Musaro A. Gene therapy for cardiac cachexia? Int J Cardiol 2002;85:185-191.
119. Rojas Vega S, Knicker A, Hollmann W, et al. Effect of resistance exercise on serum levels of growth factors in humans. Horm Metab Res 2010;42:982-986.
120. Fearon KCH. Cancer cachexia: Developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124-1132.
121. Baldwin K, Bartges J, Buffington T, et al. AAHA nutritional assessment guidelines for dogs and cats. J Am Anim Hosp Assoc 2010;46:285-296.
122. WSAVA Nutritional Assessment Guidelines Task Force Members. Nutritional assessment guidelines. J Small Anim Pract 2011;52:385-396.
123. Buffington CAT. Indoor pet initiative. The Ohio State University College of Veterinary Medicine. Available at: Accessed August 9, 2011.
124. Association of American Feed Control Officials. Official Publication. Oxford, IN: AAFCO; 2011.
125. Hutchinson D, Freeman LM, Schreiner KE, et al. Survey of opinions about nutritional requirements of senior dogs and analysis of nutrient profiles of commercially available diets for senior dogs. Int J Appl Res Vet Med 2011;9:68-79.
126. Lana SE, Kogan LR, Crump KA, et al. The use of complementary and alternative therapies in dogs and cats with cancer. J Am Anim Hosp Assoc 2006;42:361-365.
127. American College of Veterinary Nutrition website. Available at: Accessed August 9, 2011.
128. Delaney SJ. How a diplomate of the American College of Veterinary Nutrition can help your practice and patients. Compend Contin Educ Vet 2011;33:E1-E3.
129. Smith CE, Freeman LM, Rush JE, et al. Omega-3 fatty acids in Boxer dogs with arrhythmogenic right ventricular cardiomyopathy. J Vet Intern Med 2007;21:265-273.
130. Freeman LM. Beneficial effects of omega-3 fatty acids in cardiovascular disease. J Small Anim Pract 2010;51:462-470.
131. Bauer JE. Responses of dogs to dietary omega-3 fatty acids. J Am Vet Med Assoc 2007;231:1657-1661.
132. Peterson MD, Sen A, Gordon PM. Influence of resistance exercise on lean body mass in aging adults: A meta-analysis. Med Sci Sports Exerc 2011;43:249-258.
133. Glover EI, Phillips SM. Resistance exercise and appropriate nutrition to counteract muscle wasting and promote muscle hypertrophy. Curr Opin Clin Nutr Metab Care 2010;13:630-634.
134. Cheema B, Abas H, Smith B, et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: The Progressive Exercise for Anabolism in Kidney Disease (PEAK) study. Am J Kid Dis 2007;50:574-584.
135. Schulze PC, Gielen S, Schuler G, et al. Chronic heart failure and skeletal muscle catabolism: Effects of exercise training. Int J Cardiol 2002;85:141-149.